Business Wire

CA-GLOBALLOGIC

4.8.2022 05:32:14 CEST | Business Wire | Press release

Share
GlobalLogic Announces Appointment of New President and CEO

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that its President and CEO Shashank Samant will be succeeded by the firm’s current Chief Operating Officer (COO) Nitesh Banga, who will become the new President and CEO effective October 1, 2022. Nitesh is a well-rounded and seasoned executive who has successfully worked across functions from Strategy, Go-To-Market, Engineering, and Operations while also launching similar businesses in the Japan market. Shashank will assume a new role as Chairman of the GlobalLogic Board, in addition to being the Executive Advisor to Mr. Toshiaki Tokunaga, the Head of Hitachi Digital Systems and Services (DSS) Sector. In this capacity, Shashank will continue to support the GlobalLogic business as well as advise on Hitachi Group's broader digital business growth strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803006014/en/

For more than a decade as CEO, Shashank led GlobalLogic through strong growth phases during which he oversaw several strategic acquisitions and digital capability expansion efforts. His leadership and expertise took the company from a group of elite software engineers to a global digital engineering leader, eventually becoming a part of the Hitachi Group.

“I am proud of the industry leading growth we achieved during my time as GlobalLogic’s CEO,” commented Shashank. “I believe that for organizations to continue to lead and succeed, their executive leadership must also evolve. Nitesh has proven throughout his career that he is a strong leader across both vision and execution. I am confident that he will set a successful course that will take GlobalLogic through its next major growth phases. I’m also very excited to continue supporting GlobalLogic in my new role as Chairman of the Board as well as to contribute to Hitachi Group’s digital business expansion and digital transformation acceleration.”

Since his arrival in 2018, Nitesh has led critical functions of GlobalLogic’s business. He contributed significantly to GlobalLogic’s noteworthy growth while also adeptly navigating the company through monumental challenges including the COVID-19 pandemic and the war in Ukraine.

Nitesh is a services industry veteran with diversified expertise ranging across Strategy, Business Development, Service Delivery, Operations, and Mergers and Acquisitions. He has adeptly run large-scale P&L organizations and has a deep understanding of Western and Eastern cultures, including Japan. Prior to joining GlobalLogic, he spent more than two decades at IT services and consulting firm Infosys.

“It’s an honor and great responsibility to lead GlobalLogic,” said Nitesh. “The passion, expertise, and deep commitment to our clients’ success demonstrated by our employees has created an invigorating, creative institution. As we enter our third decade, we have a unique opportunity to accelerate enterprise digital transformation backed by Hitachi’s incredible heritage, global reach, and trusted brand.”

“Since GlobalLogic joined the Hitachi Group, Shashank has made significant contributions to the growth of its entire digital business. I look forward to his continued strength in helping the Hitachi Group grow and transform through digital technology,” said Keiji Kojima, President and CEO of Hitachi, Ltd. "Nitesh has had an excellent track record as COO of GlobalLogic and I am confident that he will be able to maintain the high momentum of growth in the future. We are pleased to be working with a leader of his caliber to deliver new value through innovation, Green, and Digital solutions for our customers around the world."

“With GlobalLogic becoming a part of the Hitachi Family, Hitachi’s digital capability has expanded tremendously,” said Mr. Tokunaga. “I would like to thank Shashank for his capable leadership and look forward to his contributions as Chairman of the Board. Going forward, under Nitesh's leadership, I expect GlobalLogic to continue creating synergies with Hitachi Digital and other Hitachi Group companies, and to dramatically expand the digital business through DX support for customers worldwide.”

About GlobalLogic Inc.
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com .

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye